Couragene

Couragene is a private, pre-clinical stage biotech developing a proprietary chemical engineering platform called STEP (Stimuli-responsive Traceless Engineering Platform) for the delivery of genetic medicines. The platform aims to address key limitations of current delivery vehicles like viral vectors and lipid nanoparticles, particularly for brain-targeted therapies, by creating small, cell-penetrating constructs that release their functional payload intracellularly. Early proof-of-concept data demonstrates the platform's ability to enable brain-wide gene editing in mice using a CRISPR-Cas9 construct. The company is led by a team with expertise in drug delivery, gene therapy, and clinical development.

STEP (Stimuli-responsive Traceless Engineering Platform): A chemical engineering platform that modifies genetic medicine payloads (proteins, gene editors, mRNA, etc.) to be small and cell-penetrating. The engineered construct releases the native, functional payload inside the cell in response to intracellular stimuli.

Couragene competes with viral vector engineering companies (e.g., modifying AAVs), other non-viral delivery firms (developing novel LNPs, polymers, or conjugates), and large biopharma internal efforts. Its differentiation is the sub-20nm, chemically engineered, traceless release approach aimed specifically at brain-wide delivery.